Clinical and laboratory characteristics of myelodysplastic syndrome (MDS) and acute myeloid leukemia secondary to MDS patients
| Patient characteristics . | . | RA/RARS . | RAEB . | RAEB-t/MDS-AML . |
|---|---|---|---|---|
| No. | 52 | 15 | 35 | |
| Sex | ||||
| M | 31 (60%) | 11 (73%) | 17 (49%) | |
| F | 21 (40%) | 4 (27%) | 18 (51%) | |
| Age (y) | median | 62 | 72 | 67 |
| range | (19-92) | (37-86) | (17-81) | |
| Hemoglobin (1012/dL) | median | 11.6 | 10.6 | 9.4 |
| range | (5.0-15.8) | (6.1-14.0) | (3.8-12.5) | |
| WBC (109/L) | median | 4.7 | 2.5 | 10.9 |
| range | (0.5-8.0) | (0.9-22.2) | (0.6-230.1) | |
| Neutrophils (109/L) | median | 2.5 | 0.6 | 1.4 |
| range | (0.1-5.4) | (0.2-8.5) | (0.1-13.6) | |
| Platelets (109/L) | median | 120 | 47 | 40 |
| range | (9-358) | (16-319) | (4-431) | |
| Cytogenetics | ||||
| Good risk | 38/50 (76%) | 9/14 (64%) | 8/32 (25%) | |
| Intermediate risk | 8/50 (16%) | 3/14 (21%) | 7/32 (22%) | |
| Poor risk | 4/50 (8%) | 2/14 (15%) | 17/32 (53%) | |
| Chromosome 7 abnormalities | 3/50 (6%) | 2/14 (15%) | 14/32 (44%) | |
| IPSS score | ||||
| Low | 18 (37.5%) | 0 (0%) | 0 (0%) | |
| INT-1 | 27 (56%) | 8 (62%) | 0 (0%) | |
| INT-2 | 3 (6.5%) | 4 (31%) | 0 (0%) | |
| High | 0 (0%) | 1 (6%) | 7 (100%) |
| Patient characteristics . | . | RA/RARS . | RAEB . | RAEB-t/MDS-AML . |
|---|---|---|---|---|
| No. | 52 | 15 | 35 | |
| Sex | ||||
| M | 31 (60%) | 11 (73%) | 17 (49%) | |
| F | 21 (40%) | 4 (27%) | 18 (51%) | |
| Age (y) | median | 62 | 72 | 67 |
| range | (19-92) | (37-86) | (17-81) | |
| Hemoglobin (1012/dL) | median | 11.6 | 10.6 | 9.4 |
| range | (5.0-15.8) | (6.1-14.0) | (3.8-12.5) | |
| WBC (109/L) | median | 4.7 | 2.5 | 10.9 |
| range | (0.5-8.0) | (0.9-22.2) | (0.6-230.1) | |
| Neutrophils (109/L) | median | 2.5 | 0.6 | 1.4 |
| range | (0.1-5.4) | (0.2-8.5) | (0.1-13.6) | |
| Platelets (109/L) | median | 120 | 47 | 40 |
| range | (9-358) | (16-319) | (4-431) | |
| Cytogenetics | ||||
| Good risk | 38/50 (76%) | 9/14 (64%) | 8/32 (25%) | |
| Intermediate risk | 8/50 (16%) | 3/14 (21%) | 7/32 (22%) | |
| Poor risk | 4/50 (8%) | 2/14 (15%) | 17/32 (53%) | |
| Chromosome 7 abnormalities | 3/50 (6%) | 2/14 (15%) | 14/32 (44%) | |
| IPSS score | ||||
| Low | 18 (37.5%) | 0 (0%) | 0 (0%) | |
| INT-1 | 27 (56%) | 8 (62%) | 0 (0%) | |
| INT-2 | 3 (6.5%) | 4 (31%) | 0 (0%) | |
| High | 0 (0%) | 1 (6%) | 7 (100%) |
RA indicates refractory anemia; RARS, RA with ringed sideroblasts; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; MDS-AML, acute myeloid leukemia secondary to MDS; WBC, white blood count.